This two-volume work contains the full text of the oral and poster presentations and the general discussion at the round table discussion of the Second International Conference on Alzheimer's and Parkinson's Diseases: Basic and Therapeutic Strategies, held at the Kyoto Park Hotel in Kyoto, Japan, on November 6-10, 1989. The First Conference was held at the Aviya Sonesta Hotel in Eilat, Israel, on March 24-27, 1985. , The record of this First Conference was published by Plenum Press in 1986 as Volume 29 in Advances in Behavioral Biology, under the title "Alzheimer's and Parkinson's Diseases: Strategies for Research and Development." We are happy that the comprehensive texts of the oral and poster presentations of the Second Conference could again be published within the framework of this series. Since the First Conference in 1985, rapid progress has been made in both basic and therapeutic aspects of these diseases. About 700 scientists from allover the world participated in the Second Conference, and 300 papers were presented in oral and poster sessions. Many people and organizations have helped to organize this multi disciplinary international conference and hence have contributed to the scientific quality of these two volumes. We thank the members of the organizing committee, the organizations that provided financial support, and the contributing scientists for their enthusiastic participation.
Table of ContentsMarker.- Modifications of Neuroendocrine Function during Alzheimer Type Dementia.- Preparation of Monoclonal Antibody against a Beta Protein Subpeptide and Screening for Immunoreactivity in the Sera of Patients with Alzheimer’s Disease.- Study on Vitamin B12 Levels in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease.- Serum and Cerebrospinal Fluid Vitamin B12 Levels in Demented Patients Treated with CH3-B12.- Neurochemical Markers in the Cerebrospinal Fluid of Patients with Alzheimer-Type Dementia.- The Value of Cholinergic Receptors in Blood Lymphocytes Measured by (3H)Quinuclidinyl Benzilate (3H)QNB for the Diagnosis of Cholinergic Related Dementia.- Reduced Natural Killer Cell Activity in Dementia of the Alzheimer Type.- CSF of Patients with Alzheimer’s Disease Contain Antibodies Recognizing Cholinergic Cells in the Rat CNS, and Can Protect Cholinergic Neuronal Cultures.- Alterations of Transferrin and Prealbumin in Cerebrospinal Fluid in Parkinson’s Disease.- Clinical Investigation of Neurotransmitters in Extrapyramidal System Diseases.- Total Biopterin and Neopterin Levels in the Ventricular CSF of Patients with Parkinson’s Disease.- Manganese Content in Hair of Patients with Parkinson’s Disease: Manganese Deficiency and Susceptibility towards Parkinson’s Disease.- Imaging.- Single Photon Emission Computed Tomography in Alzheimer-Type Dementia.- Application of Magnetic Resonance Imaging to a Primate Model of the Cholinergic Deficit of Alzheimer’s Disease.- In Vivo Phosphorous-31 NMR Spectroscopy in Alzheimer’s Disease.- White Matter Abnormalities on MRI in Probable Alzheimer’s Disease.- Progressive Aphasia without Global Dementia Examined by Dynamic PET Scan.- Positron Emission Tomography Studies Using 11C-Labelled Dopa and Effect of Tetrahydrobiopterin on Dopamine Release.- Striatal Presynaptic Dopaminergic Function and Cerebral Blood Flow in the MPTP Primate Model of Parkinson’s Disease by PET.- Cerebral Blood Flow (CBF) Pattern in Progressive Supranuclear Palsy and Clinico-CBF-MRI Correlations.- Nuclear Resonance Imaging in Parkinsonism Analytical Study of “Pars Compacta”.- Magnetic Resonance Imaging of Parkinson’s Disease.- Comparison of Local Cerebral Glucose and Dopamine Metabolism between Parkinson’s Disease and Parkinsonism by Positron Emission Tomography.- Striatal Dopamine D2 Receptors in Parkinson’s Disease and StriatoNigral Degeneration Determined by Positron Emission Tomography.- Clinical Aspect-1 (Alzheimer).- Alzheimer Type Dementia One or Several Disorders ?.- Quantitative Topographic Analysis of EEG in Alzheimer’s Disease.- The Concept of Subcortical Dementia (SCD): Are There Clinical Anatomical, Biochemical and Neurophysiological Basis ?.- Vascular Dementia (VD) and Primary Degenerative Dementia (PDD): Criteria for Differential Diagnosis.- Cognitive Functions in Senile Dementia of the Alzheimer Type: Interaction in the Cognitive Measures.- Is It Useful to Manage Alzheimer’s Disease as Two Clinical Subtypes: Early Onset and Late Onset Subtypes ?.- A Memory Clinic Located in a General Hospital: First Results.- Visual Cognitive Disturbance in Alzheimer’s Disease A Study by Means of Vision Analyzer as a New Method for Eye Movement.- Electrophysiological Comparison between Parkinson’s Disease and Alzheimer’s Disease.- A Clinical EEG Study of Alzheimer-Type Dementia.- A Case of Alzheimerism Induced by Trihexyphenidyl.- Probable Alzheimer’s Disease with Appearance of Periodic Synchronous Discharges for a Long Period.- Incidence and Prevalence of Alzheimer-Type Dementia: Epidemiological Investigations in 1987, 1988, and 1989.- Differences in Memory Impairment in Patients with Alzheimer’s Disease and Parkinson’s Disease with and without Dementia.- Clinical Aspect-2 (Parkinson).- Dementia in Parkinson’s Disease.- Juvenile or Early-Starting Parkinsonism as a Prototype of Nigrostriatal Dopamine Deficiency.- Clinical Features of Autòsomal Recessive Type Juvenile Parkinsonism and Improvement of Symptoms by Smoking.- The Prognostic Comparison between the Progressive Clinical Course and the Stable Course of Parkinson’s Disease Over 10 Years.- Familial Parkinson’s Disease and Familial Manic-Depressive Illness.- Neuropsychological Disturbances in Parkinson’s Disease.- Study on Incidence of Cancer and Smoking Rate in Parkinson’s Disease.- High Speed Memory Scanning in Parkinson’s Disease: Adverse Effect of L-Dopa.- Wechsler Adult Intelligence Scale and Other Related Factors for Parkinson’s Disease Patients, Main Focus: Brain Function.- Study on Relationship between Computed Tomography Brain Changes and Motor Function in Parkinson’s Disease.- A Patient Presenting Mainly Dystonia in a Family with Juvenile Parkinsonism.- Hereditary Dystonia-Parkinsonism Syndrome of Juvenile Onset with Marked Diurnal Fluctuations.- Dystonia-Parkinsonism Syndrome Showing Good Response to an AntiCholinergic Drug but Not to L-DOPA.- Neuroleptic Malignant Syndrome Associated with Withdrawal of Antiparkinsonian Drugs.- Freezing of Gait and Resistance to Dopaminergic Therapy.- Normal Thyroid Function in 50 Patients with Parkinson’s Disease.- Risk Factors to Parkinson’s Disease; Heritability and Life Styles.- Prevalence of Parkinson’s Disease in Izumo City, Japan.- Clustering of Parkinson’s Disease in Southern Israel An Endemic Parkinsonism-Impaired Vibration Sense Syndrome.- The Exteroceptive Control of Voluntary Muscle Contraction in Parkinsonism.- Exteroceptive Suppression of the Masseter and Temporalis Muscles in Patients with Parkinson’s Disease.- Mechanism of the Difficulty in Set Shifting Task in Parkinson’s Disease.- Cerebral Blood Flow, Evoked Potential and Reaction Time in Parkinson’s Disease.- Topography of Auditory Event-Related Potentials in Parkinson’s Disease.- Sleep-Wake Complaints in Parkinson’s Disease.- Estimation of Biopterin and Neopterin in Cerebrospinal Fluid in Parkinson’s Disease.- Quantitative Evaluation of Vocal Changes in Parkinson’s Disease: Intercorrelation among Voice Parameters and Monoamine Systems.- Periodic Movements During Sleep in Patients with Parkinson’s Disease.- Therapy-1(Alzheimer).- (+)-CIS-Methyl-Spiro(1,3-Oxathiolane-5,3’)Quinuclidine (AF102B): A New M1 Agonist as a Rational Treatment Strategy in Alzheimer’s Disease An Overview.- Behavioral and Neurochemical Effects of AF64A in Young and Old Fischer 344 Male Rats.- Selection of Cholinergic Agents Which May Improve Memory.- Rationale for the Planned Clinical Trials with Nerve Growth Factor in Alzheimer’s Disease.- Neurochemical and Psychopharmacological Assessment of the M1-Selective Agonist AF102B (FKS-508).- Effects of Acute and Chronic Administration of the New Muscarinic Agonist SDZ BOP-086 on Phosphoinositide Hydrolysis.- Evaluation of “Nootropic” Drug in Rats by the Radial Maze Task: Problem of Order in Administering Scopolamine and Testing Drug and Effect of a Specific Cholinergic Agonist, SDZ-210-086.- Effect of DM-9384, a New Pyrrolidone Derivative, on Passive Avoidance and Cerebral Choline Acetyltransferase Activity in Rats.- DM-9384, a Pyrrolidone Derivative, Ameliorates Basal Forebrain Lesion-Induced Amnesia and Inhibits Cycloheximide-Induced Decrease in the Number of GABA and Acetylcholine Receptors.- The Effect of Chinese Herbal Medicine TJ-23 (Toki-Syakuyaku-San) on the Choline Acetyltransferase Activity in the Cortex of Rat.- Effect of TJ-23 on Scopolamine-Induced Deficit of Learning and Memory in Rats.- Advantages of a Visual Recognition Task to Detect Cognitive Facilitation by Cholinomimetic Drugs in Primates.- Tetrahydroaminoacridine and Some of Its Analogues: Effects on the Cholinergic System.- Pharmacological Studies of Cerebroactive Drugs.- Effects of Tetrahydroaminoacridine on Passive Avoidance and Endogenous Nerve Growth Factor Levels in Rats.- SM-10888, a New Drug Candidate for Treatment of Senile Dementia of the Alzheimer Type.- Inhibitory Action of E2020, a Novel Acetylcholinesterase Inhibitor, on Cholinesterase: Comparison with Other Inhibitors.- Inhibitory Action of Nicergoline and Its Major Metabolites on Acetylcholinesterase Activity in Rat and Mouse Brain.- Changes in Discrimination Learning Ability in Rats with Ibotenic Acid-Induced Lesions in the Nucleus Basalis Magnocellularis..- SDZ ENA 713, an Acetylcholinesterase-Inhibitor with Preference for Central Activity: Animal Studies.- Development of a Cognitive Drug with the Ability to Modulate Glutamate (Glu) and Aspartate (Asp).- Nerve Growth Factor and Staurosporine Facilitate Recovery from Basal Forebrain Lesion-Induced Amnesia in Rats.- Effects of Nootropic Drugs on Experimentally Induced Amnesia of Rats in the Three-Panel Runway Task.- Effects of KW-6055, a Novel Benzylpyridine Derivative, on Brain Monoaminergic Systems of Rats.- Effects of KW-6055, a Novel Benzylpyridine Derivative, on Various Experimental Amnesia Models.- Vasopressin Fragments Improve Learning Process of Rats in the Radial Arm Maze Task.- Evaluation of Vasopressin Fragments and Their Analogues on Active Avoidance Responses of Rats with Lesions of the Dorsal Norepinephrine Bundle.- Anti-Amnestic and Anti-Anoxic Effects of Droxidopa (L-DOPS) in Animal Models.- Amelioration of Delayed Neuronal Death of the Hippocampus by Nerve Growth Factor.- Long-Term Actions of Nicotinic Receptor Stimulation in Nucleus Basalis Lesioned Rats: Blockade of Trans-Synaptic Cell Loss.- Measuring Efficacy of Reversible Cholinesterase Inhibitors for Alzheimer’s.- Quantitative Pharmaco-Electroencephalographic Study on Acetyl-LCarnitine in Geriatric Patients with Dementia.- Megavitamin Therapy (Coenzyme Q10 and Vitamin B6) in Alzheimer’s Disease and Senile Dementia of Alzheimer Type.- Therapy-2(Parkinson).- Assessment of Novel Sustained Release Antiparkinsonian Therapies in MPTP-Treated Primates.- Behavioral Effects of Dopamine-Agonists on MPTP-Induced Parkinsonism in Cynomolgus Monkeys.- Effect of Basic Fibroblast Growth Factor on Midbrain and Other CNS Neurons in Primary Culture Derived from Postnatal and Fetal Rat Brain.- Towards a Strategy for Preventing Parkinson’s Disease.- Tetrahydrobiopterin Therapy for Juvenile Parkinsonism.- Application of a Low-Protein Diet for Parkinson’s Disease.- apy for Freezing of Parkinson’s Disease.- Pharmacokinetic and Pharmacodynamic Studies with Controlled-Release Carbidopa/Levodopa.- Results of a Multicentre Study Comparing the Effects of a Controlled Release Preparation (Madopar CR) with Conventional Levodopa.- An Open Study of Evening Doses of Slow-Release L-Dopa (Madopar HBS) in Parkinson Patients with Nocturnal Disabilities.- To the Principles of Levodopa Therapy Including Slow Release Form..- A New Prodrug of L-DOPA to Attain Prolonged Plasma Concentration.- French Open Clinical Study of Modopar LP (HBS) in Parkinsonians.- Four Years of Experience in the Treatment of Parkinsonian Patients with a Controlled-Release Levodopa (HBS).- Antiparkinsonian Effects of Lisuride and Binding of the Drug to D-2 and 5-HT1A Receptors in Cynomolgus Monkeys.- Treatment of Motor Fluctuations in Parkinson’s Disease with Subcutaneous Apomorphine.- Lisuride and Proterguride Reverse MPTP-Induced Parkinsonism in the Common Marmoset.- Terguride, a Dopamine Partial Agonist for the Treatment of Parkinson’s Disease.- The Beneficial Effect of Lisuride Hydrogen Maleate in the Long Term Treatment of Parkinson’s Disease.- Selegiline in the Treatment of Daily Fluctuations in Disability A Double-Blind Study.- Pharmacological Activity of a Novel Dopamine D2 Agonist (SK&F 101468) in Man.- SK&F 101468, a Novel Dopamine D2 Agonist in Parkinson’s Disease...- Pharmacological Evaluation of SK&F 101468-A, in MPTP Treated Marmosets.- SK&F 101468-A, a Possible Drug for the Treatment of Parkinson’s Disease.- General Discussion.